Syndax Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 184
- Market Cap
- $1.7B
- Introduction
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2017-08-03
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 45
- Registration Number
- NCT03238027
- Locations
- 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Oregon Health and Science University, Portland, Oregon, United States
A Study to Evaluate the Pharmacokinetics of Entinostat in Adult Subjects With Normal and Impaired Renal Function
- First Posted Date
- 2017-06-19
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT03192111
- Locations
- 🇺🇸
New Orleans Center for Clinical Research, Knoxville, Tennessee, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT03187015
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 47
- Registration Number
- NCT02922946
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2018-08-16
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 66
- Registration Number
- NCT02922933
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT02915523
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research, Tampa, Florida, United States
🇺🇸HCA Midwest Health (SCRI Affiliate), Kansas City, Missouri, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2022-01-25
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02909452
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT02897778
- Locations
- 🇺🇸
The START Center for Cancer Care, San Antonio, Texas, United States
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2021-12-15
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 61
- Registration Number
- NCT02820961
- Locations
- 🇺🇸
Sarah Cannon Research Institute HealthONE, Denver, Colorado, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
- First Posted Date
- 2016-03-15
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT02708680
- Locations
- 🇺🇸
Ft. Wayne Hematology and Oncology, Fort Wayne, Indiana, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
🇺🇸Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States